FMP

FMP

Enter

HALO - Halozyme T...

photo-url-https://images.financialmodelingprep.com/symbol/HALO.png

Halozyme Therapeutics, Inc.

HALO

NASDAQ

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

62.27 USD

1.21 (1.94%)

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

2.76B

1.76B

1.57B

1.39B

1.38B

1.18B

1B

853.43M

727.07M

619.42M

Operating Cash Flow

134.53M

19.82M

-133.01M

76.93M

62.37M

17.84M

15.2M

12.95M

11.03M

9.4M

Cap Ex

-33.71M

-36.27M

-27.65M

-23.55M

-23.6M

-19.87M

-16.93M

-14.42M

-12.29M

-10.47M

Free Cash Flow

100.82M

-16.45M

-160.66M

53.38M

38.77M

-2.03M

-1.73M

-1.47M

-1.26M

-1.07M

Wacc

9.25

9.25

9.25

9.25

9.25

Pv Lfcf

-1.86M

-1.45M

-1.13M

-881.81k

-687.64k

Sum Pv Lfcf

-6.01M

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep